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The Affordable Care Act will provide healthcare to 31 million previously uninsured 
Americans.  Meanwhile, the country faces a growing diabetes epidemic.   25.8 
million persons are diagnosed with diabetes.  33% of the US population is predicted 
to have prediabetes, which is a strong predictor of Type II diabetes.  174 billion 
dollars were spent in 2007 treating diabetes.  If current trends continue, 1 in 3 are 
predicted to have diabetes by 2050.  These figures are not sustainable.   Exploration 
and implementation of new approaches to diabetes prevention is necessary.  After 
searching common medical research databases, four randomized controlled trials 
were reviewed.  Each article compared the use of Metformin vs lifestyle 
modifications, placebo or both in patients with prediabetes.   The comprehensive 
review suggests lifestyle modifications are superior to Metformin as the preferred 
treatment in the presence of prediabetes.  Though, Metformin was superior to 
placebo and should be considered in select patients.  Earlier intervention to prevent 
diabetes in the age of healthcare reform is cost-effective, promotes sustainability 
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DIABETES AND HEALTHCARE REFORM 
 The Centers for Disease Control (CDC) (2011) estimates that 25.8 million 
persons in the United States are currently affected by diabetes.  It is estimated that 7 
million of these persons are undiagnosed (p. 1).   It is predicted that prediabetes, a 
strong risk for Type II Diabetes, affects 33% of the US adult population.  Yet, only 
10% of persons with prediabetes are aware of their diagnosis (CDC, 2012, p. 4).  
Despite the under-diagnosis of diabetes and prediabetes, rates of diabetes tripled 
from 1990-2010.   In 2007 the direct and indirect costs of diabetes in the United 
States were estimated at $174 billion (CDC, 2011, p. 7).  Current trends predict that 
one of three adults will have diabetes by 2050 (CDC, 2012, p. 2). 
 The under-diagnosis of prediabetes and Type II Diabetes can be partially 
attributable to the high rate of Americans without health insurance.  With imminent 
implementation of the Affordable Care Act, 31 million previously uninsured 
Americans will now have access to health insurance (Rosenbaum, 2011).  
Preventative services and screenings are hallmark traits of the care act and will be 
provided without copayment or deductible. (US Department of Health and Human 
Services, 2012).  With screening comes the fundamental requirement that early 
detection of disease must lead to interventions proven to maintain health (UK 
National Screening Committee, 2011).   As 31 million newly insured Americans 
begin to access healthcare services, there will be persons who will screen positive 
for prediabetes or diabetes that would have otherwise gone undetected.  
Rates for prediabetes and diabetes will rise, as will the costs required to treat these 
disease states.  As we face the implications of healthcare reform, it is prudent to 
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explore and implement new cost-effective approaches to care.   Early intervention to 
prevent diabetes must be emphasized, considering these seismic changes to the 
healthcare delivery system.  The intent of this review is to determine if Metformin is 
superior to lifestyle modification or standard lifestyle for prevention of diabetes in 
persons meeting prediabetes criteria. 
 
PREDIABETES 
 Garber et. al (2008) define prediabetes as persons with Impaired Fasting 
Glucose (IFG) of 100-125mg/dl and/or Impaired Glucose Tolerance (IGT) of 140-
199mg/dl.  IGT is correlated with decreased insulin sensitivity and is indicative of 
higher risk for Type II Diabetes; though IGT is less practical to carry out in a 
screening format (p. 936).  Ngatena & Kapustin (2011) note research indicates 
prolonged hyperglycemic states can result in micro and macrovascular changes 
prior to the diagnosis of Type II Diabetes.   These include cardiovascular disease, 
retinopathy, nephropathy and neuropathy (p. 552-553).  Pancreatic beta-cell 
destruction begins in the presence of insulin resistance as a result of increased 
insulin secretion.  As a result, up to 50% of beta-cell mass has become compromised 
at the time overt diabetes is diagnosed.  At this extent beta-cell destruction is 
irreversible (Unger, 2007, p. 733).  Progression of cardiovascular disease resulting 
from hyperglycemia begins prior to the diagnosis of Diabetes (p. 735).  Therefore, it 
is becoming increasingly accepted that fasting glucose of 99mg/dl is the upper limit 
of normal (Garber et. al, 2008, p. 936). 
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 Garbert et.al, (2008) state 6-10% of persons with IGT progress to overt 
diabetes annually.  For those with combined IGT and IFG, the 6-year risk is 
potentially as high as 65% (p. 936).  If glycemic goals can be achieved early in the 
progression of diabetes, beta-cell function can be preserved and risk for vascular 
complications become significantly reduced (Unger, 2007, p. 733).  This warrants 
exploration of earlier interventions for prevention of Type II Diabetes and 
associated vascular manifestations of hyperglycemic states.  A joint statement on 
behalf of the American College of Endocrinology (ACE) and the American Association 
of Clinical Endocrinologists (AACE)recommend screening for diabetes in patients 
with any one of the following: 
• Family History of Diabetes 
• Cardiovascular Disease 
• Obesity/Overweight 
• Sedentary Lifestyle 
• Non-white ancestry 
• History of IGT, OFT and/or Metabolic Syndrome 
• Hypertension 
• Dyslipidemia 
• History of Gestational Diabetes 
• Polycystic Ovarian Syndrome 
• Active antipsychotic therapy by pharmacologic means (Garber et. al. 2008, p. 
936-937). 
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 Meanwhile, the Agency for Healthcare Research and Quality (AHRQ) (2008) 
recommends screening for Type 2 diabetes only in the presence of blood pressure 
greater than 135/80.   AHRQ maintains “there is inadequate evidence that early 
diabetes control as a result of screening provides an incremental benefit for 
microvascular clinical outcomes compared with treatment after clinical diagnosis” 
(AHRQ, 2008).  AHRQ states short and long-term harms of detection or early 
treatment is minimally significant. 
 
METFORMIN 
 Edmunds and Mayhew (2009) state Metformin’s primary mechanism of 
action works by decreasing hepatic glucose production, thereby decreasing overall 
serum glucose levels. Decreased serum glucose levels prompt decreased insulin 
production from the pancreas causing less stress on beta cells.   Metformin reduces 
HgbA1C levels by 0.9%-1.4%.    Metformin does not potentiate hypoglycemia, 
rendering it a relatively safe medication (p. 573).  It can only be used in renal 
competent individuals.  Renal function is measured at the start of therapy and 
monitored as necessary.  In rare circumstances, Metformin can induce lactic 
acidosis, which should be considered in patients with significant acute illness.  
Metformin should not be used in patients diagnosed with Congestive Heart Failure.  
Gastrointestinal side effects such as bloating, flatulence, and nausea are common 
when starting the medication but generally resolve in first 1-2 weeks of therapy 
(Edmunds & Mayhew, 2009, p. 578).  
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 Consumer Reports (2011) note the monthly cost of generic Metformin 
averages $7-$24, which includes extended release formulations (p. 22-23).  
Metformin is approved by the Food and Drug Administration (FDA) for the 
treatment of Type II and is the most common first-line monotherapy.  Micromedex 
(2012) notes Diabetes mellitus prophylaxis is not an FDA-labeled indication for use 
of Metformin.  Other non-FDA labeled indications includes: Gestational Diabetes 
Prophylaxis, Polycystic Ovary Syndrome and Antipsychotic-pharmacotherapy 
induced weight gain (Micromedex, 2012). 
 
LIFESTYLE MODIFICATION 
 Lifestyle modification in the presence of prediabetes has been directed 
towards reduction of serum glucose through adherence to improved diet.  Improved 
insulin sensitivity occurs by skeletal muscle uptake of glucose through improved 
insulin transport of glucose.  This occurs through weight loss and physical activity.  
As a result, Rosenzwig et.al (2008) recommend lifestyle modifications to include 
weight loss of 5-10% in the first year of therapy and routine physical activity of 
moderate intensity for at least 30 minutes, but preferably 45-60 minutes.  This 
should be done at least 5 days of the week.  Dietary recommendations include low 
fat, high fiber, unprocessed grains and the avoidance of foods with high glycemic 
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 The literature review utilized common search engines such as CINHAL and 
Medline.  Quantitative, randomized, control trials evaluating the use of Metformin in 
prediabetes were sought.   Quality of studies was evaluated using the Critical 
Appraisal Skills Programme (2010) research appraisal tool.  The following four 
articles were reviewed. 
 
EFFECT OF METFORMIN ON PATIENTS WITH IMPAIRED GLUCOSE TOLERANCE 
 C.L. Li et al. (1999) randomized 90 subjects to either Metformin – 250mg 
three times daily or placebo in double-blind fashion.  Subjects were drawn from a 
process that screened over 29,000 employees of an industrial corporation 
throughout Beijing, China.  Inclusion criteria were those with IGT on two different 
occasions.  Exclusion criteria included those who had been on metformin in the past 
or those with cardiac, renal or hepatic disease (p. 478).  Patient education pertaining 
to diet, exercise, healthy lifestyle, diabetes knowledge, and symptom recognition 
were performed at visits on a three-month basis.  The outcome measure was the 
incidence of diabetes after 12 months of therapy  (Lin et al. 1999, p. 478). 
 Li et al. (1999) reported that 70 subjects remained in the study at the 12-
month completion of the study.   20 subjects were lost primarily due to lack of pill 
compliance in both groups.  
 Of the 33 that remained in the metformin group, 28 (84.9%, P=0.0001) 
reverted to normal glucose tolerance.  Fasting glucose decreased from the 
equivalence of 124.2mg/dl at start to 90mg/dl (P=0.0001).  Glycosylated 
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hemoglobin decreased from 7.3 to 6.6 (P=0.0001).  The metformin group also 
experienced significant decreases in serum insulin levels.  One person (3.0% 
converted to frank diabetes (Lin et al., 1999, p. 479). 
 Of the 37 that remained in the placebo group, 19 (51.4%, P=0.0001) reverted 
to normal glucose tolerance. 6 patients (16.2%, P=0.0001) converted to type II 
diabetes.  Fasting glucose decreased from 131.4mg/dl to 111.6mg/dl (P=0.0001).  
Glycosylated hemoglobin decreased minimally from 7.4 to 7.3 (P=0.0001).   Overall 
there was an increase in serum insulin levels (p. 479).  In summary, Li et. al’s (1999) 
study suggests that Metformin is superior to placebo in the prevention of diabetes in 
persons with IGT.  Though, there is evidence to suggest that basic diabetes 
education is beneficial given the decrease in fasting glucose in the placebo group. 
 This randomized, double-blinded control study is clearly defined with its 
intent, control and design.  The population is clearly defined, but is limited to 
industrial workers in Beijing.  Thus, cultural limitations apply when attempting to 
generalize to other populations.   Age, sex and baseline measures are similar in both 
groups.   A limitation is that fasting glucose in the placebo group is higher and could 
be considered overt diabetes.  Confidence intervals for statistics are not provided, 
but P-values close to zero represent the data’s strong statistical significance.  
Specifics of the education material and application into lifestyles would be helpful, 
given the decrease in fasting glucose in both groups.  The quality of this study is also 
affected by the small sample size. 
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DIABETES PREVENTION PROGRAM RESEARCH GROUP 
 The most comprehensive study to date is conducted by the Diabetes 
Prevention Program (DPP).  Knowler et.al (2002), as part of the DPP, conducted a 
randomized control trial of 3,234 participants from 27 healthcare centers that 
quantitatively evaluated the prevention of diabetes.  Inclusion criteria required 
either IGT: 140-199mg/dl or IFG: 95-125mg/dl.  Participants were required to be 25 
year of age or older with a body mass index of 24 or greater.  Participants were 
randomly assigned to one of the three following groups:  Standard lifestyle plus 
Metformin (n=1073); standard lifestyle plus placebo (n=1082); intensive lifestyle 
modification (n=1079).  Metformin was given at 850mg twice daily. Intensive 
lifestyle included a goal weight reduction of 7% of initial body weight through 
healthy diet and physical activity of moderate intensity for at least 150 minutes 
weekly (Knowler et.al, 2002, p. 394). 
 38% percent of the intensive lifestyle modification group maintained the 7% 
weight loss goal at time of publication.  58% had met the goal of 150 minutes of 
exercise per week. For those taking Metformin, 72% were able to accomplish 80% 
adherence to therapy.  For those in the placebo group 77% were able to achieve 
80% adherence to therapy (Knowler et al, 2002, p. 395-396). 
 The primary outcome for this study was the 3-year incidence of diabetes; 
defined by either a fasting glucose of greater than 126mg/dl or glucose greater than 
200mg/dl after a 75-gram glucose load.  The three-year incidence of diabetes was: 
11 cases per 100 person years in the placebo group; 7.8 cases in the in the 
Metformin group; 4.8 in the intensive lifestyle modification group (P=<0.05).  When 
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compared to placebo this rendered an incidence of diabetes percentage that was 
58% lower (95% confidence interval: 48-66%) in the Intensive Lifestyle 
Modification group and 31% lower (95% CI: 17-43%) in the Metformin group.   The 
3-year incidence of diabetes was estimated to be 28.9% for the placebo group, 
21.7% in the Metformin group and 14.4 in the Intensive Lifestyle group (Knowler, 
2002, p. 398).  
 In summary, the Diabetes Prevention Program’s study suggests that intense 
lifestyle modification with predetermined weight loss goals, dietary modification 
and 150 minutes of exercise per week is the superior approach to the prevention of 
diabetes in those with IGT and/or IFG.  The study also suggests that Metformin is 
superior to placebo in the prevention of diabetes. 
 This strength of this study was its large size with subjects gathered from 
multiple care centers.  This avoids social, gender or racial bias and allows for better 
generalization to other populations.   Interventions and control groups were clearly 
defined.  Participants were evenly distributed amongst the three randomized 
groups.  Baseline characteristics such as gender, race, age, weight/BMI, and baseline 
physical activity were very evenly distributed.  This reflects the benefit of a large-
scale, randomized study.  Optimal p-values and narrow confidence intervals 
rendered high statistical quality.  Study personnel and participants were blinded if 
they were in the placebo or Metformin group.  Incidence of diabetes was the 
primary measure of the study.  Adherence was also addressed.  Weight loss was 
another component that was evaluated but not included for purposes of this review.  
Each intervention was deemed safe and placed participants at minimal risk.  Neither 
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Metformin nor intense lifestyle modification has been declared the standard of care 
for persons with prediabetes.  Thus, participant groups were not denied a known, 
optimal care method.  None of the interventions were serious threats to participant 
safety.   
 
INDEPENDENT AND COMBINED EFFEECTS OF EXERCISE TRAINING AND 
METFORMIN  
 Malin, Chipkin, Gerber & Braun (2012) took a small sample size to 
quantitatively evaluate the combined effect of Metformin and exercise training.  
Outcome measures were changes in insulin sensitivity, serum insulin levels and 
fasting glucose levels over 12 weeks.   Results were compared to each intervention 
individually.  32 participants in the Amherst, Massachusetts community were 
randomized equally into four groups: placebo; metformin; exercise training with 
placebo; exercise training with metformin.  The study was conducted in a double-
blind fashion.  Participant inclusion criteria included an abnormal IGT.   Exclusion 
criteria included smokers, those with recent significant weight changes and those 
with chronic disease such as respiratory, renal, and heart disease (p. 131-132). 
 Participants randomized into a Metformin group were gradually increased in 
dosing to 2,000mg daily.  Compliance with placebo and metformin was greater than 
90%.  Participants randomized into an exercise-training group were subjected to 
supervised, structured exercise sessions of 60-75 minutes in duration, 3 times per 
week.  Insulin sensitivity and serum insulin levels were monitored via systematic 
laboratory methods (Malin et.al, 2012, p. 132-133). 
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 At the conclusion of the 12-week study, fasting glucose levels did not vary 
amongst the four groups.  Serum insulin levels increased from 120.8pmol/L to 
129.5pmol/L in the placebo group.  Serum insulin levels decreased in every other 
group: Metformin – 144.4pmol/L to 100.8 pmol/L; exercise plus placebo – 
83.1pmol/l to 73.1pmol/L; exercise plus Metformin – 92.9pmol/L to 75.8pmol/L 
(Malin et al. 2012, p. 135). 
 The most notable finding in the study, which is not included in other studies, 
was the decrease in insulin sensitivity when Metformin was added to the exercise 
group.  Insulin sensitivity decreased in the placebo group: Ra – 12.97 to 10.89.  
Insulin sensitivity increased in both exercise alone: Ra – 9.20 to 14.12 and 
metformin alone: Ra 7.94 to 9.01.  Insulin sensitivity was essentially unaffected in 
the combined exercise/metformin group: Ra – 11.08 to 11.42 (Malin et. al, 2012, p. 
135). 
 Malin et. al (2012) propose that Metformin might have inhibited the benefits 
of insulin sensitivity in comparison to exercise alone.  This hypothesis is derived 
from the fact that Metformin’s mechanism of action directly inhibits normal cellular 
changes during exercise (p. 134).  Malin et. al suggest exercise training is the 
primary mechanism in promoting increased insulin sensitivity in persons with IGT.  
Metformin, used alone or in combination with exercise, does benefit fasting glucose 
and serum insulin levels. 
 The study conducted by Malin et. al (2012) is limited by its small sample size 
and varied baseline statistics amongst the four groups.  Though intensive insulin 
sensitivity and radiographic weight monitoring necessitates a small sample. The 
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quality of data through confidence interval was not readily available, also limiting its 
quality.  Participants were randomized in double-blind fashion.  All participants 
were followed through the conclusion of the 12-week study.  There were more 
women in the placebo group; otherwise the groups were nearly equal from a gender 
perspective.  It was noted that a large majority of participants were of Caucasian 
decent.  The sample was derived from a small area of Massachusetts, so application 
to the general population is limited.  Insulin sensitivity, fasting glucose and serum 
insulin were all statistically significant (P=<0.05) findings in the study.   
 
ASIAN INDIAN DIABETES PREVENTION PROGRAMME 
 Ramachandran et. al’s (2005) study note persons of Asian-Indian decent are 
genetically prone to IGT and insulin resistance at a young age despite lower than 
average body mass index (BMI).  Persistent IGT was defined as impaired glucose 
tolerance on two separate glucose tolerance tests.  531 middle-class participants 
ages 33-55 were randomized into four groups: control; lifestyle modification; 
metformin; and lifestyle modification plus metformin.  Metformin was started at 
500mg twice-daily for 40 days but then decreased to 250mg twice-daily secondary 
to reported hypoglycemic symptoms.  Lifestyle modification included education 
about appropriate diet and regular physical activity.   The primary outcome was the 
3-year incidence of diabetes, defined as fasting serum glucose of >126mg/dl and/or 
2 hour glucose >200mg/dl following 75-gram glucose load. 
 502 of the subjects, 95%, completed the 3-year follow up.  44% developed 
diabetes (Ramachandran, 2005, p. 295).  The control group’s 3-year incidence of 
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diabetes is 55% (CI 95% 46.0 – 63.5).  The incidence of diabetes in the lifestyle 
modification group is 39.3% with a relative risk reduction of 28.5% (CI 95% - 20.5-
37.3. p=0.018) in comparison to control.  The incidence of diabetes in the metformin 
group is 40.5% with a risk reduction of 26.4% (CI 95% - 19.1-35.1 p=0.029). The 
incidence of diabetes in the combined lifestyle modification-metformin group is 
39.5% with a risk reduction of 28.2% (CI 95% - 20.3-37.0 p=0.022) (p. 293). 
 At the conclusion of the study, 81.5% of the lifestyle modification group 
adhered to dietary modifications, while 81.9% of the combined lifestyle 
modification-metformin group adhered to diet.  Physical activity was adhered to by 
58.8% by the lifestyle modification group while 62.9% of the combined lifestyle-
metformin group adhered to the physical activity criteria.  Lastly, 90.9% of the 
metformin group adhered to the drug regimen, while 95.1% of the combined 
lifestyle-metformin group adhered to the metformin regimen.   
 In summary, Ramachandran et.al (2005) suggest that lifestyle modification is 
the preferred approach in the prevention of diabetes in persons with IGT who are 
genetically prone to prediabetic states.  A combined lifestyle modification and 
Metformin approach offers benefits that are slightly inferior to lifestyle 
modification.  Metformin used alone offers significant benefits in comparison to 
placebo but are slightly less preferred in comparison to the lifestyle modification 
groups. 
 Ramachandran et.al’s (2005) study is strong in its randomized, controlled 
format.  However, it is not double blinded.  The Asian-Indian population is culturally 
unique given the prevalence of IGT despite normal BMI.  Thus, generalization 
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beyond the study population is hindered.  The study included predominantly male 
subjects in all groups.  Each group was composed of similar age categories.  
Unskilled/skilled workers were evenly predominant in all categories.  Baseline 
fasting glucose and glucose tolerance, A1C and fasting insulin levels were similar in 
all groups (p. 292). 
 
DISCUSSION 
 Increased screening for diabetes through the implementation of the 
Affordable Care Act will capture a large percentage of persons with undiagnosed 
prediabetes and type II diabetes.  This potentiates a significant increase to the 
already burdensome financial costs the US already spends on the diabetes epidemic.  
Herman et.al (2012) found that 10 years of the Diabetes Prevention Program 
resulted in both lifestyle modifications and metformin being more cost-effective in 
comparison to placebo (p. 727).  Furthermore, research is beginning to suggest that 
vascular effects of persistent, non-diabetic hyperglycemia have begun to progress. 
For these reasons, healthcare providers must strongly consider earlier screening 
and therapeutic intervention in the prevention of diabetes. 
 Adopting more expansive screening criteria should be considered a first step 
in achieving such goals.  ACE/AACE joint recommendation looks to capture more 
persons at risk for diabetes.  Meanwhile, the more widely utilized AHRQ 
recommends screening only when elevated blood pressure is present.  This may not 
be in the best interest of the patient considering the progressing vascular 
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abnormalities in persistent hyperglycemic states.  Therefore, healthcare providers 
should consider adopting ACE/AACE recommendations into practice. 
 When prediabetes is confirmed, the literature review recommends the 
implementation of lifestyle modifications as the first-line approach to prevent overt 
type II diabetes.  Garber et.al (2008) suggest sustained weight loss of 5-10% (p. 
938).  Hamman et.al (2006) suggest that each 1kg of weight loss through intensive 
lifestyle modification may result in a 16% decrease in diabetes risk (p. 2105).  To 
attain weight loss goals, physical activity of moderate intensity 30-60 minutes 5 
days a week should be strongly encouraged.  A diet of restricted calories, low-
carbohydrate, high fiber, and low fat should also be encouraged (Garber, 2008, p. 
938).  The provider should collaborate on an individual basis with each patient in 
how to best achieve these outcomes with respect to cultural, social and individual 
lifestyle preferences. 
 Patients with prediabetes qualify for glucose screening biannual basis based 
on Medicare guidelines (Department of Health and Human Services, N.D.).  At 
minimum this should guide follow up.  In addition to glucose screening, patients 
with prediabetes should be monitored regularly for progression towards weight-
loss goals.  Discussion and encouragement surrounding adherence to lifestyle 
modifications such as diet and physical exercise should also take place. 
 While literature supports lifestyle modification is preferred as the first line 
approach, there are circumstances that Metformin is preferred.  Metformin has 
shown to reduce fasting glucose levels and serum insulin levels in comparison to 
placebo.  Metformin may be considered as first-line therapy in patients with 
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prediabetes who knowingly will not, or are physically unable to, adhere to lifestyle 
modifications.  Starting Metformin may be further indicated in the presence of 
multiple comorbidities such as coronary artery disease, hypertension, obesity, 
hyperlipidemia once risks and benefits are considered.  If, through continued follow 
up, lifestyle modification goals are not being met, a collaborative discussion 
regarding the risks and benefits of starting Metformin should take place. 
 Early legislation for increasing prediabetes resources is in progress.  
Representative DeGette has written legislation in 2011 for Medicare coverage of 
Medical Nutrition Therapy (MNT) for patients with prediabetes (Congressional 
Diabetes Caucus, 2011).  MNT has proven effective in patients with diabetes and the 
concepts can be applied to individuals with prediabetes.  Providers and the 
healthcare community must advocate for such legislation that expands services for 
the prevention of type II diabetes. 
 Research repeatedly supports physical activity as the optimal approach in 
the prevention of diabetes.  The structure for physical activity varied in the 
literature.  Research surrounding optimal regimens is warranted and should be 
advocated for.  As research begins to promote such regimens, advocacy for 
insurance reimbursement for such programs should be supported.  Standards for 
practice should then follow. 
 A fundamental value driving the Affordable Care Act is that all individuals 
have a right to healthcare.  Implementation of the act is complicated by the excess 
cost of care in the current healthcare delivery system.  To ensure sustainability 
during these seismic changes, different approaches to care must be considered.  Any 
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changes that ensue must maintain quality outcomes the population expects.  
Persistent treatment of treating diabetes with either lifestyle modifications or 
metformin meets these objectives by preventing costly treatment and management 
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